Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Genentech Stories

2013-08-14 23:24:36

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Shawn Carter from Genentech will be speaking at Pharmica’s SharePoint West Conference October 28 & 29, 2013 in San Francisco, CA. San Francisco, CA (PRWEB) August 14, 2013 Pharmica Consulting has long filled the role of being life science experts in marrying business processes to new systems and technologies. Pharmica will host its annual SharePoint Conferences in San...

2013-08-14 08:27:06

Treatment Rates with Avastin in Endometrial Cancer are Low but Most Surveyed Oncologists Believe that Angiogenesis Inhibitors Can Play a Role in Treatment of Endometrial Cancer, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for...

2013-08-13 12:26:41

Moreover, the Majority of Oncologists Who Have Not Yet Prescribed Perjeta Intend to Do So in the Next Three Months, According to a New Report from BioTrends Research Group EXTON, Pa., Aug. 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one year post-launch, the user-base of Roche/Genentech/Chugai's Perjeta has more than doubled since BioTrends first assessed physician...

2013-08-07 08:30:31

CereKin(TM) (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, Aug. 7, 2013 /PRNewswire/ -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has initiated a pivotal clinical trial for CereKin(TM) (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of...

2013-08-04 23:01:26

RnRMarketResearch.com adds latest report on “Research Report on Global and China Monoclonal Antibody Industry, 2013-2017” to its store. Dallas, Texas (PRWEB) August 04, 2013 Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In...

2013-07-24 08:29:48

PITTSBURGH, July 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This product is the generic version of TARCEVA(®), and is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or...

2013-07-10 08:28:42

Regardless of First-Line Therapy Choice, Treatment Typically Occurs Within Same Month As Wet AMD Diagnosis, According to a New Report from BioTrends Research Group EXTON, Pa., July 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal anti-vascular endothelial...

2013-07-08 16:26:43

NEWARK, Calif., July 8, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of Louis J. Lavigne, Jr. to the company's Board of Directors, and to the Board's Audit Committee. Mr. Lavigne is the former Executive Vice President and Chief Financial Officer of Genentech. "Lou is a highly skilled life sciences veteran with experience leading companies through extraordinary growth. His insight and breadth of expertise in strategy, finance and operations will...

2013-07-04 23:01:48

ReportsnReports.com adds reports on Cancer Diagnostic & Therapy Market for Esophageal, Thyroid and Metastatic Breast to its store. Dallas, Texas (PRWEB) July 04, 2013 These reports ''Esophageal Cancer - Pipeline Review, H1 2013'', ''Thyroid Cancer - Pipeline Review, H1 2013” and “Metastatic Breast Cancer – Pipeline Review, H1 2013”, provide an overview of the indication’s therapeutic pipeline. These reports provide information on the therapeutic...

2013-06-27 23:20:05

BioPlus selected as a specialty pharmacy for the new Tarceva network; now authorized to dispense this oncology medication. Altamonte Springs, FL (PRWEB) June 27, 2013 The medication Tarceva® (erlotinib) from Genentech and Astellas Pharma US, Inc. will no longer be distributed through retail pharmacies, effective July 1, 2013. Tarceva will be supplied through BioPlus Specialty Pharmacy (BioPlus) and other select specialty pharmacies. Tarceva is a once daily oral non-chemotherapy...